Healthcare · Drug Manufacturers - Specialty & Generic
Price
$31.69
Market Cap
$1.3B
Employees
1,940
Beta
0.46
Avg Volume
356,253
CEO
Jack Clifford Bendheim
Business Description
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
Business History
Price Overview
Last updated: Jun 27, 2026 9:05am (just now)$31.69
-0.14 (-0.44%)
Day Range
$31.25 – $32.28
52-Week Range
$25.33 – $60.08
50-Day MA
$39.66
200-Day MA
$43.23
Volume
417,786.00
Analyst Price Targets
Low
$49.00
Consensus
$49.00
High
$49.00
(7 analysts)
Share Structure
Outstanding
40,538,416.00
Float
40,238,472.00
Free Float
99.3%
High free float
— 99.3% of shares trade freely, ~0.7% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
13.49
Stock Price: $31.69
EPS (Diluted): 1.19
EPS (Diluted): 1.19
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.62
Stock Price: $31.69
Total Equity: $285.68M
Shares: 40,700,000
Total Equity: $285.68M
Shares: 40,700,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
8.95
Market Cap: $1.28B
Total Debt: $718.69M
Cash: $68.04M
EBITDA: $146.85M
Total Debt: $718.69M
Cash: $68.04M
EBITDA: $146.85M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$1.7B
Market Cap: $1.28B
Total Debt: $718.69M
Cash: $68.04M
Total Debt: $718.69M
Cash: $68.04M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
30.9%
Gross Profit: $399.94M
Revenue: $1.30B
Revenue: $1.30B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
8.5%
Operating Income: $110.47M
Revenue: $1.30B
Revenue: $1.30B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
3.7%
Net Income: $48.26M
Revenue: $1.30B
Revenue: $1.30B
ROE (Profit from shareholder equity)
APINet Income / Total Equity
29.5%
Net Income: $48.26M
Total Equity: $285.68M
Total Equity: $285.68M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
11.4%
Operating Income: $110.47M
Tax Rate: 29.0%
Equity: $285.68M
Total Debt: $718.69M
Cash: $68.04M
Tax Rate: 29.0%
Equity: $285.68M
Total Debt: $718.69M
Cash: $68.04M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.76
Current Assets: $810.61M
Current Liabilities: $293.47M
Current Liabilities: $293.47M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
2.52
Short-Term Debt: $16.25M
Long-Term Debt: $702.44M
Total Debt: $718.69M
Total Equity: $285.68M
Long-Term Debt: $702.44M
Total Debt: $718.69M
Total Equity: $285.68M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$31.85
Revenue: $1.30B
Shares: 40,700,000
Shares: 40,700,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$7.02
Total Equity: $285.68M
Shares: 40,700,000
Shares: 40,700,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$1.03
Operating CF: $80.12M
CapEx: -$38.29M
Shares: 40,700,000
CapEx: -$38.29M
Shares: 40,700,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
1.9%
Last Dividend: N/A
Stock Price: $31.69
Stock Price: $31.69
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $48.26M
Net Income: $48.26M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares PAHC against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 24, 2026 6:37pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $833.4M | $942.3M | $977.9M | $1.0B | $1.3B |
| Cost of Revenue | $562.0M | $656.9M | $679.7M | $704.6M | $896.3M |
| Gross Profit | $271.4M | $285.4M | $298.2M | $313.1M | $399.9M |
| Operating Expenses | $196.5M | $206.4M | $226.4M | $259.8M | $289.5M |
| Operating Income | $74.9M | $79.0M | $71.8M | $53.3M | $110.5M |
| Net Income | $54.4M | $49.2M | $32.6M | $2.4M | $48.3M |
| EBITDA | $110.2M | $117.1M | $106.0M | $69.1M | $146.8M |
| EPS | $1.34 | $1.21 | $0.81 | $0.06 | $1.19 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 6:37pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $50.2M | $74.2M | $41.3M | $70.6M | $68.0M |
| Total Current Assets | $498.9M | $566.2M | $585.7M | $601.0M | $810.6M |
| Total Assets | $841.3M | $931.7M | $971.4M | $982.2M | $1.4B |
| Current Liabilities | $164.1M | $190.8M | $176.0M | $204.1M | $293.5M |
| Long-Term Debt | $382.7M | $417.9M | $452.5M | $458.3M | $702.4M |
| Total Liabilities | $602.8M | $669.3M | $688.9M | $725.5M | $1.1B |
| Total Equity | $238.5M | $262.4M | $282.5M | $256.6M | $285.7M |
| Retained Earnings | $218.0M | $247.7M | $260.9M | $243.9M | $272.7M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 6:37pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $48.3M | $31.6M | $13.3M | $87.6M | $80.1M |
| Capital Expenditure | -$29.3M | -$37.0M | -$51.8M | -$41.2M | -$38.3M |
| Free Cash Flow | $19.0M | -$5.4M | -$38.5M | $46.4M | $41.8M |
| Acquisitions (net) | $29.3M | -$13.5M | $0 | -$3.3M | -$286.5M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $13.9M | $24.0M | -$33.0M | $29.3M | -$2.6M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 9:05am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$1.5B $1.5B – $1.6B
|
$1.6B $1.6B – $1.6B
|
$1.6B $1.6B – $1.7B
|
$1.7B $1.7B – $1.7B
|
| EBITDA |
$169.0M $167.9M – $169.8M
|
$174.7M $174.7M – $174.7M
|
$180.0M $178.3M – $180.9M
|
$185.4M $183.7M – $186.3M
|
| Net Income |
$136.1M $129.9M – $142.2M
|
$149.5M $148.1M – $150.9M
|
$177.5M $175.3M – $178.6M
|
$196.6M $194.2M – $197.8M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 6:37pm (2d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +13.1% | +3.8% | +4.1% | +27.4% |
| Gross Profit Growth | +5.2% | +4.5% | +5.0% | +27.7% |
| Operating Income Growth | +5.5% | -9.0% | -25.8% | +107.2% |
| Net Income Growth | -9.6% | -33.7% | -92.6% | +1,897.7% |
| EBITDA Growth | +6.3% | -9.5% | -34.9% | +112.6% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-29 | CORCORAN E THOMAS | P-Purchase | 10,000.00 | $31.77 | $317,700 |
| 2026-05-05 | BENDHEIM JACK | S-Sale | 6,264.00 | $55.73 | $349,071 |
| 2026-05-05 | BENDHEIM JACK | S-Sale | 776.00 | $56.37 | $43,739 |
| 2026-05-06 | BENDHEIM JACK | S-Sale | 5,634.00 | $57.18 | $322,125 |
| 2026-05-06 | BENDHEIM JACK | S-Sale | 1,406.00 | $58.13 | $81,725 |
| 2026-05-07 | BENDHEIM JACK | S-Sale | 1,350.00 | $47.59 | $64,248 |
| 2026-05-07 | BENDHEIM JACK | S-Sale | 1,149.00 | $48.31 | $55,505 |
| 2026-05-07 | BENDHEIM JACK | S-Sale | 2,029.00 | $49.19 | $99,815 |
| 2026-04-28 | BENDHEIM JACK | S-Sale | 1,652.00 | $55.10 | $91,019 |
| 2026-04-28 | BENDHEIM JACK | S-Sale | 4,591.00 | $56.06 | $257,375 |
| 2026-04-28 | BENDHEIM JACK | S-Sale | 797.00 | $56.69 | $45,182 |
| 2026-04-29 | BENDHEIM JACK | S-Sale | 4,002.00 | $52.70 | $210,907 |
| 2026-04-29 | BENDHEIM JACK | S-Sale | 3,038.00 | $53.21 | $161,645 |
| 2026-04-30 | BENDHEIM JACK | S-Sale | 5,805.00 | $52.65 | $305,618 |
| 2026-04-30 | BENDHEIM JACK | S-Sale | 1,235.00 | $53.32 | $65,848 |
| 2026-04-21 | BENDHEIM JACK | S-Sale | 1,625.00 | $55.35 | $89,944 |
| 2026-04-21 | BENDHEIM JACK | S-Sale | 5,415.00 | $56.17 | $304,137 |
| 2026-04-22 | BENDHEIM JACK | S-Sale | 7,040.00 | $54.29 | $382,185 |
| 2026-04-23 | BENDHEIM JACK | S-Sale | 6,619.00 | $54.07 | $357,857 |
| 2026-04-23 | BENDHEIM JACK | S-Sale | 421.00 | $54.56 | $22,969 |
Dividend History (Last 20)
Last updated: Jun 24, 2026 6:37pm (2d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-03 | $0.12 | 2026-05-05 | 2026-06-03 | 2026-06-24 |
| 2026-03-04 | $0.12 | 2026-02-03 | 2026-03-04 | 2026-03-25 |
| 2025-11-26 | $0.12 | 2025-11-04 | 2025-11-26 | 2025-12-17 |
| 2025-09-03 | $0.12 | 2025-07-29 | 2025-09-03 | 2025-09-24 |
| 2025-06-04 | $0.12 | 2025-05-06 | 2025-06-04 | 2025-06-25 |
| 2025-03-05 | $0.12 | 2025-02-04 | 2025-03-05 | 2025-03-26 |
| 2024-11-27 | $0.12 | 2024-11-05 | 2024-11-27 | 2024-12-18 |
| 2024-09-04 | $0.12 | 2024-07-30 | 2024-09-04 | 2024-09-25 |
| 2024-06-05 | $0.12 | 2024-05-07 | 2024-06-05 | 2024-06-26 |
| 2024-03-05 | $0.12 | 2024-02-06 | 2024-03-06 | 2024-03-27 |
| 2023-11-28 | $0.12 | 2023-11-06 | 2023-11-29 | 2023-12-20 |
| 2023-09-05 | $0.12 | 2023-07-25 | 2023-09-06 | 2023-09-27 |
| 2023-06-06 | $0.12 | 2023-05-01 | 2023-06-07 | 2023-06-28 |
| 2023-02-28 | $0.12 | 2023-02-06 | 2023-03-01 | 2023-03-22 |
| 2022-11-29 | $0.12 | 2022-11-07 | 2022-11-30 | 2022-12-21 |
| 2022-09-06 | $0.12 | 2022-07-25 | 2022-09-07 | 2022-09-28 |
| 2022-05-31 | $0.12 | 2022-05-02 | 2022-06-01 | 2022-06-22 |
| 2022-03-01 | $0.12 | 2022-02-07 | 2022-03-02 | 2022-03-23 |
| 2021-11-23 | $0.12 | 2021-11-01 | 2021-11-24 | 2021-12-15 |
| 2021-08-31 | $0.12 | 2021-07-26 | 2021-09-01 | 2021-09-22 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for PAHC — it's generated by the pipeline (
market-narrative step).
No community reviews yet for PAHC.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30